To The Editor
In a recent issue of International Ophthalmology, Ozdal et al. [1] wrote about cyclooxygenase-2 expression in human irradiated uveal melanomas. They reported that radiotherapy may actually decrease cycloxygenase-2 expression in uveal melanomas. This is of great clinical significance as almost 90 % of all uveal melanomas are immunoreactive for cycloxygenase-2 [2] . In fact, increased cycloxygenase-2 expression by uveal melanomas is associated with a worse prognosis.
Cycloxygenase-2 inhibitors such as celecoxib have already been shown to inhibit tumor growth in cutaneous melanomas and cycloxygenase-2 may very well be an ideal target molecule to inhibit carcinogenesis in uveal melanomas [3] . For instance, Marshall et al. [4] have recently demonstrated the effectiveness of a topical cycloxygenase inhibitor nepafenac in delaying tumor progression in animal models. Fernandes et al. [5] have also shown that amfenac (the active metabolite of nepafenac) increases the sensitivity of the tumor cells to radiotherapy. In fact, radiotherapy may very well have a synergistic effect with amfenac in inhibiting uveal melanoma cells. Interestingly, Souza et al. [6] have also reported increased cycloxygenase-2 expression in retinoblastomas.
Clearly, cycloxygenase-2 has a major role to play in the evolution and progression of ocular tumors. Given the massive potential that anti-cycloxygenase therapies such as nepafenac and radiotherapy have in the management of uveal melanomas, there is a clear and urgent need for further human studies to fully explore their potency and effectiveness in the management of these tumors.
